Surgical Snare Market Size and Share

Surgical Snare Market Analysis by Mordor Intelligence
The surgical snare market stands at USD 1.67 billion in 2025 and is projected to reach USD 2.06 billion by 2030, reflecting a steady 4.38% CAGR. Growth aligns with rising colorectal-cancer screening volumes, broader adoption of AI-assisted detection systems, and the transition toward cold-snare polypectomy that improves safety profiles. Ambulatory surgery centers (ASCs) now perform 72% of United States procedures at 45-60% lower costs than hospital settings, sharply increasing demand for single-use snares. Demographic tailwinds from aging populations further sustain procedure volumes, while technology leaders differentiate through shape optimization and artificial intelligence rather than price competition. Quality-assurance challenges, including recent recalls of single-use guide sheath kits, underscore the need for robust clinical evidence and post-market surveillance to protect adoption trajectories.
Key Report Takeaways
- By usability, single-use devices held 68.36% of the surgical snare market share in 2024; reusable devices lagged as infection-control priorities intensified.
- By application, gastrointestinal endoscopy commanded 64.72% revenue share in 2024, while urology endoscopy is forecast to expand at a 5.24% CAGR through 2030.
- By shape, oval designs led with 41.28% share in 2024; crescent designs are projected to grow at 4.73% CAGR to 2030.
- By end-user, hospitals accounted for 56.64% of 2024 revenue, whereas ASCs are advancing at a 5.42% CAGR on the back of procedure migration.
- By geography, North America contributed 43.26% of 2024 revenue; Asia-Pacific is the fastest-growing region at 5.76% CAGR through 2030.
Global Surgical Snare Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Rising preference for minimally-invasive surgeries | +1.2% | Global, with highest adoption in North America & Europe | Medium term (2-4 years) |
Expansion of endoscopic ambulatory surgery centers | +0.8% | North America core, expanding to APAC | Long term (≥ 4 years) |
Hospital investments in advanced endoscopy suites | +0.6% | Global, concentrated in developed markets | Medium term (2-4 years) |
Intensifying colorectal-cancer screening programs | +0.9% | Global, with accelerated adoption in APAC | Long term (≥ 4 years) |
Increasing adoption of cold-snare polypectomy techniques | +0.4% | North America & Europe, spreading to APAC | Short term (≤ 2 years) |
AI-enabled snare devices enhancing detection & resection efficiency | +0.5% | Developed markets initially, global expansion | Medium term (2-4 years) |
Source: Mordor Intelligence
Rising Preference for Minimally-Invasive Surgeries
Patient demand for faster recovery and lower complication rates is shifting procedural volumes toward endoscopic techniques. Device requirements now emphasize precise tissue capture through small lumens, favoring cold-snare designs compatible with robotic-assisted platforms. Seventeen robotic endoscopy systems remain under development, while nine hold regulatory approval. ASCs leverage this trend to attract cases, forecasting 25% volume growth over the next decade. The preference boosts the surgical snares market as clinicians standardize on single-use snares to secure sterility. Vendors that bundle AI-enabled visualization with snares gain additional traction in value-focused health systems.
Expansion of Endoscopic Ambulatory Surgery Centers
Thirty new gastrointestinal ASCs opened in 2023, illustrating a structural shift away from inpatient settings.[1]Journal of Clinical Medicine, “Global Growth of GI ASCs,” jofcm.org CMS supports site-neutral reimbursement and plans a 2.6% ASC rate update for 2025, raising total payments to USD 7.4 billion. Private-equity funding accelerates network build-out in metropolitan areas, increasing standardized purchasing of disposable snares. Since ASCs emphasize quick turnover and infection control, the single-use segment of the surgical snares market expands faster than the reusable segment. Manufacturers that design procedure-specific kits gain purchasing preference as administrators seek inventory simplification.
Hospital Investments in Advanced Endoscopy Suites
Hospitals upgrade endoscopy infrastructure to protect complex case volumes and meet value-based reimbursement criteria. Micro-Tech launched the EdgeHog Hot Snare in 2025 to improve endoscopic mucosal resection performance. STERIS validated its Exacto Cold Snare, achieving 91% complete resection versus 79% for legacy snares.[2]STERIS, “Exacto Cold Snare Clinical Data,” steris.com These data support premium pricing and strengthen vendor-provider relationships. Investment in 4K imaging and AI decision support further elevates snare performance expectations. Hospitals often lock into long-term supply contracts to secure technology upgrades, stabilizing revenue for leading manufacturers in the surgical snares market.
Intensifying Colorectal-Cancer Screening Programs
Guidelines lowering the screening age to 45 expand eligible populations. Denmark’s participation rate sits at 74.9%, while Bulgaria trails at 6.3%. China relies on community-based risk stratification, and Thailand cites cost as a barrier for 25% of citizens. Device makers that deliver value-engineered snares address emerging-market affordability challenges. FDA clearance of the ColoSense non-invasive test broadens the funnel of patients referred to endoscopy. Growing procedure volumes reinforce long-run demand across the surgical snares market.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Post-polypectomy bleeding & perforation risks | -0.3% | Global, with higher impact in developing markets | Short term (≤ 2 years) |
Reimbursement cuts for GI endoscopy procedures | -0.7% | North America & Europe primarily | Medium term (2-4 years) |
Stringent approval pathway for single-use devices | -0.4% | Global, with EU MDR creating highest barriers | Long term (≥ 4 years) |
Shift toward endoscopic submucosal dissection tools | -0.2% | APAC leading, gradual adoption elsewhere | Long term (≥ 4 years) |
Source: Mordor Intelligence
Post-Polypectomy Bleeding and Perforation Risks
Cold snare techniques record 10.8% immediate bleeding compared with 3.2% for hot snare use, though delayed bleeding rates favor cold techniques. Liability exposure therefore influences device selection and training requirements. Regulators intensify clinical-evidence demands, particularly under the European Medical Device Regulation that mandates enhanced safety data. Manufacturers with established surveillance systems and rigorous post-market follow-up capitalize despite the hurdle. Emerging markets feel the risk more acutely due to limited emergency capacity, which moderates short-term uptake in high-volume centers.
Reimbursement Cuts for GI Endoscopy Procedures
Medicare finalized a 2.83% physician fee schedule reduction for 2025, compounding a 33% inflation-adjusted decline over 15 years. Commercial insurers often follow CMS trends, leading providers to constrain device budgets. Some hospitals weigh a return to reusable snares despite infection control benefits of disposables. Conversely, Japan granted reimbursement for AI computer-aided detection in colonoscopy during 2024, indicating that clear clinical benefit can still command premium pricing. Manufacturers that prove efficiency gains and reduce adverse events offset downward reimbursement pressure, sustaining share in the surgical snares market.
Segment Analysis
By Usability: Single-Use Dominance Reshapes Economics
Single-use devices captured 68.36% of the surgical snares market share in 2024. The segment should advance at 4.89% CAGR to 2030 as infection-control mandates override per-procedure cost concerns. Recent contamination incidents involving reusable endoscopes push purchasers toward disposable options. However, rising waste management costs and new European packaging rules effective August 2026 create sustainability pressures on single-use models. Cardinal Health collected 18.3 million single-use items for recycling in 2024, showcasing emerging circular-economy responses.
Reusable snares remain relevant in high-volume centers that operate validated sterilization workflows. These facilities highlight lower lifetime costs compared with the USD 797–USD 4,400 per procedure expense for single-use duodenoscopes. Yet EU Medical Device Regulation compliance raises ongoing testing costs for reusables, narrowing the savings gap. Given the current adoption curve, the surgical snares market size for single-use devices will surpass USD 1.3 billion by 2030, representing a majority of incremental revenue. Providers increasingly demand eco-friendly materials to mitigate landfill impact, prompting vendors to explore biodegradable polymers.

Note: Segment shares of all individual segments available upon report purchase
By Shape: Oval Leadership Faces Crescent Innovation
Oval designs held 41.28% market share in 2024, underscoring physician familiarity and broad lesion applicability. Crescent designs, however, post the fastest 4.73% CAGR to 2030 due to superior capture efficiency in flat lesions and favorable ergonomics in the right colon. Early clinical evidence shows crescent snares improving complete resection rates for lateral spreading tumors. Vendors respond by integrating micro-serrated wire edges to enhance tissue grip.
Specialized shield and hexagonal shapes address niche anatomical scenarios but account for a smaller slice of the surgical snares market. The Exacto Cold Snare’s shield shape yielded 91% complete resection versus 79% for traditional ovals, highlighting the performance boost that shape optimization can deliver. Demand for AI-guided navigation systems could accelerate adoption of shape-specific snares because algorithms prefer devices with predictable curvature profiles. As these innovations mature, the surgical snares market size for crescent designs could reach USD 590 million by 2030.
By Application: GI Endoscopy Dominance Amid Urology Surge
Gastrointestinal endoscopy maintained 64.72% share in 2024, benefiting from guideline-expansion and high global colorectal-cancer incidence. Urology procedures form the fastest-growing application at 5.24% CAGR through 2030, propelled by rising stone disease prevalence and improved 4K visualization such as the camera launched by Olympus in September 2024. Laparoscopy and gynecology contribute steady growth, driven by minimally-invasive adoption across broader surgical indications.
Emerging AI software that identifies bladder lesions or common bile duct stones in real time will further lift demand in non-GI specialties. The surgical snares market size for urology could climb above USD 210 million by 2030 from a low base, diversifying revenue streams for established endoscopy brands. Application-specific snares, such as those optimized for flexible ureteroscopes, amplify competitive differentiation beyond generic GI solutions.

Note: Segment shares of all individual segments available upon report purchase
By End-User: Hospital Leadership Challenged by ASC Growth
Hospitals delivered 56.64% of 2024 revenue due to complex case handling and established procurement contracts. Yet ASCs are projected to grow at a 5.42% CAGR through 2030 as 21% procedure volume migration is expected, totaling 44 million ASC cases by 2034. Specialty clinics focus on selective procedures like inflammatory bowel disease surveillance, preferring single-use snares that simplify inventory.
ASC buyers value standardized kits that shorten turnover times, reinforcing single-use momentum. Vendors that can supply bulk-priced yet premium-featured snares will capture this high-growth channel. Reimbursement parity initiatives and expanding covered procedure codes reinforce the case shift, narrowing cost differentials with hospitals and funneling incremental demand into the surgical snares market.
Geography Analysis
North America led with 43.26% of 2024 revenue, underpinned by mature screening programs, robust ASC infrastructure, and early adoption of AI decision support. Growth through 2030 sits at 4.2% as value-based care rewards high resection completeness and low complication rates.[3]ASC Focus, “ASC Procedure Migration Forecast,” ascfocus.org FDA scrutiny following safety recalls prompts providers to favor manufacturers with transparent real-world evidence. The surgical snare market size in North America is expected to exceed USD 830 million by 2030, with single-use penetration topping 75%.
Europe presents a sophisticated regulatory environment anchored by the EU Medical Device Regulation. Higher approval costs create competitive moats for compliant suppliers, while environmental policy drives recyclable packaging mandates starting 2026. Germany, France, and the Nordic region continue to invest in AI CADe systems, positioning the surgical snare market for steady 4.1% CAGR despite reimbursement headwinds. Hospitals increasingly sign multiyear strategic agreements to secure evidence-backed snare designs and training services.
Asia-Pacific posts the fastest 5.76% CAGR through 2030 due to infrastructure expansion and screening guideline adoption. China continues to pilot community screening programs, and Japan’s decision to reimburse AI colonoscopy tools in 2024 boosts technology demand. Cost sensitivity persists in Thailand and Indonesia, steering buyers toward value-engineered devices. Local manufacturing partnerships reduce import duties and strengthen regional competitiveness. By 2030, Asia-Pacific could contribute 30% of global surgical snare market revenue, narrowing the gap with North America.

Competitive Landscape
The surgical snare market displays moderate concentration. Olympus, Boston Scientific, and Cook Medical combine long tenures, comprehensive portfolios, and extensive clinical data to defend leadership. Olympus derived 63.8% of its FY 2025 sales, or ¥997.3 billion, from Endoscopic Solutions. Boston Scientific closed acquisitions worth USD 3.7 billion for Axonics and USD 1.26 billion for Silk Road Medical in 2024, signaling an appetite for consolidation that widens barriers to entry.
Emerging differentiation lies in AI-enabled detection, recyclable materials, and shape-specific performance. Mid-tier players such as CONMED and Merit Medical pursue niche indications and regional markets. CONMED posted USD 321.3 million revenue in Q1 2025 and raised full-year outlook on robust endoscopy growth. Karl Storz acquired Asensus Surgical in 2024 to secure robotic capability at USD 0.35 per share. Patent portfolios covering micro-serrated wire and low-friction coatings create tactical defenses against commoditization.
Pricing remains relatively stable as hospitals and ASCs prioritize proven safety over low cost. The 2025 recall of Olympus single-use guide sheath kits after 26 serious injuries underscores the importance of post-market vigilance. Firms that combine design innovation with clinical surveillance are best positioned to expand share. As AI integration and sustainability standards rise, competitive advantage will hinge on meeting both clinical and environmental benchmarks across the surgical snare market.
Surgical Snare Industry Leaders
-
Cook Medical
-
CONMED Corporation
-
Medline Industries
-
Olympus Corporation
-
Boston Scientific Corporation
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- January 2025: Olympus acquired Sur Medical SpA, its longstanding Chilean distributor, to establish direct presence in the Chilean market.
- November 2024: American Journal of Gastroenterology published data showing 10.8% immediate bleeding with cold snare polypectomy versus 3.2% with hot snare techniques for pedunculated polyps ≤10 mm.
- May 2024: Videogie reported favorable outcomes for bipolar hot snare polypectomy on intermediate lesions.
- March 2024: STERIS study confirmed Exacto Cold Snare achieved 91% complete resection compared with 79% for conventional snares.
Global Surgical Snare Market Report Scope
As per the scope of the report, the surgical snare is a device used for eliminating polyps and another extended stalk of tissue growth by slicing them off at the base. This report is segmented by Usability, Application, End-user, and Geography.
By Usability | Reusable Surgical Snares | ||
Single-Use Surgical Snares | |||
By Shape | Oval | ||
Crescent | |||
Hexagonal | |||
Others | |||
By Application | Gastrointestinal Endoscopy | ||
Laparoscopy | |||
Urology Endoscopy | |||
Gynecology / Obstetrics Endoscopy | |||
Others | |||
By End-User | Hospitals | ||
Ambulatory Surgical Centers | |||
Specialty Clinics | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Reusable Surgical Snares |
Single-Use Surgical Snares |
Oval |
Crescent |
Hexagonal |
Others |
Gastrointestinal Endoscopy |
Laparoscopy |
Urology Endoscopy |
Gynecology / Obstetrics Endoscopy |
Others |
Hospitals |
Ambulatory Surgical Centers |
Specialty Clinics |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current value of the surgical snare market?
The market is valued at USD 1.67 billion in 2025 and is projected to reach USD 2.06 billion by 2030 at a 4.38% CAGR.
Which segment dominates the surgical snare market?
Single-use snares lead with 68.36% share in 2024 due to strong infection-control preferences across hospitals and ASCs.
Which geographic region is growing the fastest?
Asia-Pacific posts the highest 5.76% CAGR through 2030 thanks to expanding screening programs and rising healthcare investments.
How do reimbursement trends affect the market?
A 2.83% Medicare fee schedule cut for 2025 pressures provider budgets, yet devices that show clear clinical benefits, such as AI-enabled systems, still secure premium reimbursement in select regions.
Page last updated on: June 29, 2025